Area of research
Oncology · Otorhinolaryngology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Head and Neck Cancer Studies, Cancer Research and Treatments, and Nutrition and Health in Aging.
Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol
Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer (OPC).
Patient-derived head and neck cancer organoids allow treatment stratification and serve as a tool for biomarker validation and identification
The association between skeletal muscle measures and chemotherapy‐induced toxicity in non‐small cell lung cancer patients
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study
Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer
Accurate detection of circulating tumor DNA using nanopore consensus sequencing
First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer
The association of cisplatin pharmacokinetics and skeletal muscle mass in patients with head and neck cancer: The prospective PLATISMA study
Validation of skeletal muscle mass assessment at the level of the third cervical vertebra in patients with head and neck cancer
Patterns, Predictors, and Prognostic Value of Skeletal Muscle Mass Loss in Patients with Locally Advanced Head and Neck Cancer Undergoing Cisplatin-Based Chemoradiotherapy
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer
The Predictive Value of Low Skeletal Muscle Mass Assessed on Cross-Sectional Imaging for Anti-Cancer Drug Toxicity: A Systematic Review and Meta-Analysis
The predictive and prognostic value of low skeletal muscle mass for dose-limiting toxicity and survival in head and neck cancer patients receiving concomitant cetuximab and radiotherapy
Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis
Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours
Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment
Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole
Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular‐signal‐regulated kinase and DNA in circulating tumor cells
Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin